Dr. Kim takes over for Michael Sumner, MD, who has been in the role since 2013, according to an Oct. 26 press release.
Dr. Kim will be located at the company’s U.S. subsidiary in Morristown, N.J., and will lead the U.S. medical affairs department.
He will also work closely with the pharmaceutical team in Sweden on the development of Orexo’s AmorphOX platform, which focuses on innovative treatments for patients with substance abuse disorders.
Prior to his new role, Dr. Kim worked as a psychiatrist for 13 years before joining Biohaven Pharmaceuticals as its vice president and head of medical affairs.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
